Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine ± cusatuzumab in newly diagnosed AML unfit for intensive therapy
2024-510991-19-00Phase 2Authorised
- Sponsor
- OncoVerity
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) comparing Venetoclax + azacitidine + cusatuzumab with Venetoclax + azacitidine (2 arms). Primary endpoint: Overall survival. Planned start Aug 2024; status: authorised.
02
Drugs
venetoclaxazacitidinecusatuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-510991-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510991-19-00.